An exploratory study to assess the antihypertensive effect of Esaxerenone in hypertensive patients, and its correlation with Urinary Na / K ratio or salt intake.

Katsuya Tomohiro0 个研究点目标入组 126 人开始时间: 2021年8月25日最近更新: 2024年4月23日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 126

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Esaxerenone significantly reduced morning home BP as well as bedtime home and office BP, and also significantly decreased NT-proBNP and UACR in patients with essential hypertension inadequately controlled with an ARB or a CCB. These effects were consistent regardless of concomitant use of antihypertensive drugs (ARB and CCB) and were achieved without clinically relevant serum potassium elevation or any new safety concerns.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 ot applicable（—）
性别: All

入选标准

•Patients will be included if they meet all of the following inclusion criteria:
•1) Patients aged 20 years or older at informed consent
•2) Hypertensive patients treated with an antihypertensive drug (ARB or CCB) at regular dose for at least 4 weeks prior to the first day of Esaxerenone treatment
•3) Patients with a mean systolic blood pressure =>125 mmHg and/or diastolic blood pressure =>75 mmHg in the last 5 days of early morning home blood pressure measured by a brachial sphygmomanometer

排除标准

•Patients who meet any of the following criteria will be excluded.
•1) Patients diagnosed with secondary hypertension (endocrine hypertension, hypertension due to single kidney, etc.)
•2) Hyperkalemia patients or patients whose serum potassium level exceeds 5.0 mEq/L
•3) Patients with severe renal impairment (eGFR< 30 mL/min/1.73m2).
•4) Patients with severe liver dysfunction (liver failure, cirrhosis, etc.)
•5) Patients hospitalized for myocardial infarction/heart failure, underwent percutaneous coronary angioplasty/coronary artery bypass surgery, and developed cerebral infarction/cerebral hemorrhage/subarachnoid hemorrhage/transient ischemic attack within 12 weeks before obtaining informed consent.
•6) Patients diagnosed with life expectancy within one year due to some diseases
•7) Patients diagnosed with dementia
•8) Pregnant, possibly pregnant, breast-feeding or planning to become pregnant
•9) Patients who are inappropriate for this study judged by their primary physicians

研究者

发起方

Katsuya Tomohiro

相似试验

已完成

4 期

Japan Morning Surge-1 StudyHypertension

NCT00285519Japan Heart Foundation600

已完成

不适用

ESES-LVH study

JPRN-jRCTs071190043Tsujita Kenichi60

已完成

2 期

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart FailureHeart Failure

NCT00923156Novartis Pharmaceuticals123

已完成

4 期

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 HypertensionHypertension

NCT00853957Novartis443

终止

3 期

PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)Type 1 Diabetes

NCT00729365Northwestern University65